Table of Content - Pulmonary Arterial Hypertension Market Size, Share 2032 | MRFR

Pulmonary Arterial Hypertension Market Segmentation

Pulmonary Arterial Hypertension Drug Class Outlook (USD Billion, 2019-2032)

Prostacyclin and Prostacyclin Analogs

SGC Stimulators

Endothelin Receptor Antagonists (ERAs)

PDE-5 Inhibitors

Pulmonary Arterial Hypertension Type Outlook (USD Billion, 2019-2032)

Branded

Generics

Pulmonary Arterial Hypertension Route of Administration Outlook (USD Billion, 2019-2032)

Oral

Intravenous/subcutaneous

Inhalational

Pulmonary Arterial Hypertension Regional Outlook (USD Billion, 2019-2032)

North America Outlook (USD Billion, 2019-2032)
- North America Pulmonary Arterial Hypertension by Drug Class
  - Prostacyclin and Prostacyclin Analogs
  - SGC Stimulators
  - Endothelin Receptor Antagonists (ERAs)
  - PDE-5 Inhibitors
- North America Pulmonary Arterial Hypertension by Type
  - Branded
  - Generics
- North America Pulmonary Arterial Hypertension by Route of Administration
  - Oral
  - Intravenous/subcutaneous
  - Inhalational
- US Outlook (USD Billion, 2019-2032)
- US Pulmonary Arterial Hypertension by Drug Class
  - Prostacyclin and Prostacyclin Analogs
  - SGC Stimulators
  - Endothelin Receptor Antagonists (ERAs)
  - PDE-5 Inhibitors
- US Pulmonary Arterial Hypertension by Type
  - Branded
  - Generics
- US Pulmonary Arterial Hypertension by Route of Administration
  - Oral
  - Intravenous/subcutaneous
  - Inhalational
- CANADA Outlook (USD Billion, 2019-2032)
- CANADA Pulmonary Arterial Hypertension by Drug Class
  - Prostacyclin and Prostacyclin Analogs
  - SGC Stimulators
  - Endothelin Receptor Antagonists (ERAs)
  - PDE-5 Inhibitors
- CANADA Pulmonary Arterial Hypertension by Type
  - Branded
  - Generics
- CANADA Pulmonary Arterial Hypertension by Route of Administration
  - Oral
  - Intravenous/subcutaneous
  - Inhalational
- Europe Outlook (USD Billion, 2019-2032)
  - Europe Pulmonary Arterial Hypertension by Drug Class
    - Prostacyclin and Prostacyclin Analogs
    - SGC Stimulators
    - Endothelin Receptor Antagonists (ERAs)
    - PDE-5 Inhibitors
  - Europe Pulmonary Arterial Hypertension by Type
    - Branded
    - Generics
  - Europe Pulmonary Arterial Hypertension by Route of Administration
    - Oral
    - Intravenous/subcutaneous
    - Inhalational
  - Germany Outlook (USD Billion, 2019-2032)
  - Germany Pulmonary Arterial Hypertension by Drug Class
    - Prostacyclin and Prostacyclin Analogs
    - SGC Stimulators
    - Endothelin Receptor Antagonists (ERAs)
    - PDE-5 Inhibitors
  - Germany Pulmonary Arterial Hypertension by Type
    - Branded
    - Generics
  - Germany Pulmonary Arterial Hypertension by Route of Administration
    - Oral
    - Intravenous/subcutaneous
    - Inhalational
  - France Outlook (USD Billion, 2019-2032)
  - France Pulmonary Arterial Hypertension by Drug Class
    - Prostacyclin and Prostacyclin Analogs
    - SGC Stimulators
    - Endothelin Receptor Antagonists (ERAs)
    - PDE-5 Inhibitors
  - France Pulmonary Arterial Hypertension by Type
    - Branded
    - Generics
  - France Pulmonary Arterial Hypertension by Route of Administration
    - Oral
    - Intravenous/subcutaneous
    - Inhalational
  - UK Outlook (USD Billion, 2019-2032)
  - UK Pulmonary Arterial Hypertension by Drug Class
    - Prostacyclin and Prostacyclin Analogs
    - SGC Stimulators
    - Endothelin Receptor Antagonists (ERAs)
    - PDE-5 Inhibitors
  - UK Pulmonary Arterial Hypertension by Type
    - Branded
    - Generics
  - UK Pulmonary Arterial Hypertension by Route of Administration
    - Oral
    - Intravenous/subcutaneous
    - Inhalational
  - ITALY Outlook (USD Billion, 2019-2032)
  - ITALY Pulmonary Arterial Hypertension by Drug Class
    - Prostacyclin and Prostacyclin Analogs
    - SGC Stimulators
    - Endothelin Receptor Antagonists (ERAs)
    - PDE-5 Inhibitors
  - ITALY Pulmonary Arterial Hypertension by Type
    - Branded
    - Generics
  - ITALY Pulmonary Arterial Hypertension by Route of Administration
    - Oral
    - Intravenous/subcutaneous
    - Inhalational
  - SPAIN Outlook (USD Billion, 2019-2032)
  - Spain Pulmonary Arterial Hypertension by Drug Class
    - Prostacyclin and Prostacyclin Analogs
    - SGC Stimulators
    - Endothelin Receptor Antagonists (ERAs)
    - PDE-5 Inhibitors
  - Spain Pulmonary Arterial Hypertension by Type
    - Branded
    - Generics
  - Spain Pulmonary Arterial Hypertension by Route of Administration
    - Oral
    - Intravenous/subcutaneous
    - Inhalational
  - Rest Of Europe Outlook (USD Billion, 2019-2032)
  - Rest Of Europe Pulmonary Arterial Hypertension by Drug Class
    - Prostacyclin and Prostacyclin Analogs
    - SGC Stimulators
    - Endothelin Receptor Antagonists (ERAs)
    - PDE-5 Inhibitors
  - REST OF EUROPE Pulmonary Arterial Hypertension by Type
    - Branded
    - Generics
  - REST OF EUROPE Pulmonary Arterial Hypertension by Route of Administration
    - Oral
    - Intravenous/subcutaneous
    - Inhalational
  - Asia-Pacific Outlook (USD Billion, 2019-2032)
    - Asia-Pacific Pulmonary Arterial Hypertension by Drug Class
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
    - Asia-Pacific Pulmonary Arterial Hypertension by Type
      - Branded
      - Generics
    - Asia-Pacific Pulmonary Arterial Hypertension by Route of Administration
      - Oral
      - Intravenous/subcutaneous
      - Inhalational
    - China Outlook (USD Billion, 2019-2032)
    - China Pulmonary Arterial Hypertension by Drug Class
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
    - China Pulmonary Arterial Hypertension by Type
      - Branded
      - Generics
    - China Pulmonary Arterial Hypertension by Route of Administration
      - Oral
      - Intravenous/subcutaneous
      - Inhalational
    - Japan Outlook (USD Billion, 2019-2032)
    - Japan Pulmonary Arterial Hypertension by Drug Class
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
    - Japan Pulmonary Arterial Hypertension by Type
      - Branded
      - Generics
    - Japan Pulmonary Arterial Hypertension by Route of Administration
      - Oral
      - Intravenous/subcutaneous
      - Inhalational
    - India Outlook (USD Billion, 2019-2032)
    - India Pulmonary Arterial Hypertension by Drug Class
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
    - India Pulmonary Arterial Hypertension by Type
      - Branded
      - Generics
    - India Pulmonary Arterial Hypertension by Route of Administration
      - Oral
      - Intravenous/subcutaneous
      - Inhalational
    - Australia Outlook (USD Billion, 2019-2032)
    - Australia Pulmonary Arterial Hypertension by Drug Class
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
    - Australia Pulmonary Arterial Hypertension by Type
      - Branded
      - Generics
    - Australia Pulmonary Arterial Hypertension by Route of Administration
      - Oral
      - Intravenous/subcutaneous
      - Inhalational
    - Rest of Asia-Pacific Outlook (USD Billion, 2019-2032)
    - Rest of Asia-Pacific Pulmonary Arterial Hypertension by Drug Class
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
    - Rest of Asia-Pacific Pulmonary Arterial Hypertension by Type
      - Branded
      - Generics
    - Rest of Asia-Pacific Pulmonary Arterial Hypertension by Route of Administration
      - Oral
      - Intravenous/subcutaneous
      - Inhalational
    - Rest of the World Outlook (USD Billion, 2019-2032)
      - Rest of the World Pulmonary Arterial Hypertension by Drug Class
        
        Prostacyclin and Prostacyclin Analogs
        
        SGC Stimulators
        
        Endothelin Receptor Antagonists (ERAs)
        
        PDE-5 Inhibitors
      - Rest of the World Pulmonary Arterial Hypertension by Type
        
        Branded
        
        Generics
      - Rest of the World Pulmonary Arterial Hypertension by Route of Administration
        
        Oral
        
        Intravenous/subcutaneous
        
        Inhalational
      - Middle East Outlook (USD Billion, 2019-2032)
      - Middle East Pulmonary Arterial Hypertension by Drug Class
        
        Prostacyclin and Prostacyclin Analogs
        
        SGC Stimulators
        
        Endothelin Receptor Antagonists (ERAs)
        
        PDE-5 Inhibitors
      - Middle East Pulmonary Arterial Hypertension by Type
        
        Branded
        
        Generics
      - Middle East Pulmonary Arterial Hypertension by Route of Administration
        
        Oral
        
        Intravenous/subcutaneous
        
        Inhalational
      - Africa Outlook (USD Billion, 2019-2032)
      - Africa Pulmonary Arterial Hypertension by Drug Class
        
        Prostacyclin and Prostacyclin Analogs
        
        SGC Stimulators
        
        Endothelin Receptor Antagonists (ERAs)
        
        PDE-5 Inhibitors
      - Africa Pulmonary Arterial Hypertension by Type
        
        Branded
        
        Generics
      - Africa Pulmonary Arterial Hypertension by Route of Administration
        
        Oral
        
        Intravenous/subcutaneous
        
        Inhalational
      - Latin America Outlook (USD Billion, 2019-2032)
      - Latin America Pulmonary Arterial Hypertension by Drug Class
        
        Prostacyclin and Prostacyclin Analogs
        
        SGC Stimulators
        
        Endothelin Receptor Antagonists (ERAs)
        
        PDE-5 Inhibitors
      - Latin America Pulmonary Arterial Hypertension by Type
        
        Branded
        
        Generics
      - Latin America Pulmonary Arterial Hypertension by Route of Administration
        
        Oral
        
        Intravenous/subcutaneous
        
        Inhalational

Leading companies partner with us for data-driven Insights

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS

6.1. Overview

6.2. Prostacyclin and Prostacyclin Analogs

6.3. SGC Stimulators

6.4. Endothelin Receptor Antagonists (ERAs)

6.5. PDE-5 Inhibitors

7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE

7.1. Overview

7.2. Branded

7.3. Generics

8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION

8.1. Overview

8.2. Oral

8.3. Intravenous/subcutaneous

8.4. Inhalational

9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY REGION

9.1. Overview

9.1. North America

9.1.1. US

9.1.2. Canada

9.2. Europe

9.2.1. Germany

9.2.2. France

9.2.3. UK

9.2.4. Italy

9.2.5. Spain

9.2.6. Rest of Europe

9.3. Asia-Pacific

9.3.1. China

9.3.2. India

9.3.3. Japan

9.3.4. South Korea

9.3.5. Australia

9.3.6. Rest of Asia-Pacific

9.4. Rest of the World

9.4.1. Middle East

9.4.2. Africa

9.4.3. Latin America

10. COMPETITIVE LANDSCAPE

10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategy in the Global Pulmonary Arterial Hypertension Market,

10.5. Competitive Benchmarking

10.6. Leading Players in Terms of Number of Developments in the Global Pulmonary Arterial Hypertension Market,

10.7. Key developments and Growth Strategies

10.7.1. New Product Launch/Service Deployment

10.7.2. Merger & Acquisitions

10.7.3. Joint Ventures

10.8. Major Players Financial Matrix

10.8.1. Sales & Operating Income, 2023

10.8.2. Major Players R&D Expenditure, 2023

11. COMPANY PROFILES

11.1. United Therapeutics Corporation

11.1.1. Company Overview

11.1.2. Financial Overview

11.1.3. Products Offered

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Johnson & Johnson

11.2.1. Company Overview

11.2.2. Financial Overview

11.2.3. Products Offered

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Viatris Inc.

11.3.1. Company Overview

11.3.2. Financial Overview

11.3.3. Products Offered

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. Bayer

11.4.1. Company Overview

11.4.2. Financial Overview

11.4.3. Products Offered

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. Sandoz Inc.

11.5.1. Company Overview

11.5.2. Financial Overview

11.5.3. Products Offered

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. Gilead Sciences, Inc.

11.6.1. Company Overview

11.6.2. Financial Overview

11.6.3. Products Offered

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Lupin Pharmaceuticals, Inc.

11.7.1. Company Overview

11.7.2. Financial Overview

11.7.3. Products Offered

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. GlaxoSmithKline

11.8.1. Company Overview

11.8.2. Financial Overview

11.8.3. Products Offered

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. Novartis International AG

11.9.1. Company Overview

11.9.2. Financial Overview

11.9.3. Products Offered

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Teva Pharmaceutical Industries Ltd.

11.10.1. Company Overview

11.10.2. Financial Overview

11.10.3. Products Offered

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

11.11. Sun Pharmaceutical Industries, Inc.

11.11.1. Company Overview

11.11.2. Financial Overview

11.11.3. Products Offered

11.11.4. Key Developments

11.11.5. SWOT Analysis

11.11.6. Key Strategies

12. APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, SYNOPSIS, 2019-2032

TABLE 2 GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)

TABLE 3 GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)

TABLE 4 GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 5 GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 6 NORTH AMERICA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)

TABLE 7 NORTH AMERICA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 8 NORTH AMERICA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 9 US: PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)

TABLE 10 US: PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 11 US: PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 12 CANADA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)

TABLE 13 CANADA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 14 CANADA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 1 EUROPE: PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)

TABLE 2 EUROPE: PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 3 EUROPE: PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 4 GERMANY: PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)

TABLE 5 GERMANY: PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 6 GERMANY: PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 7 FRANCE: PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)

TABLE 8 FRANCE: PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 9 FRANCE: PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 10 ITALY: PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)

TABLE 11 ITALY: PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 12 ITALY: PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 13 SPAIN: PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)

TABLE 14 SPAIN: PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 15 SPAIN: PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 16 UK: PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)

TABLE 17 UK: PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 18 UK: PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 19 REST OF EUROPE: PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)

TABLE 20 REST OF EUROPE: PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 21 REST OF EUROPE: PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 22 ASIA-PACIFIC: PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)

TABLE 23 ASIA-PACIFIC: PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 24 ASIA-PACIFIC: PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 25 JAPAN: PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)

TABLE 26 JAPAN: PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 27 JAPAN: PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 28 CHINA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)

TABLE 29 CHINA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 30 CHINA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 31 INDIA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)

TABLE 32 INDIA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 33 INDIA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 34 AUSTRALIA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)

TABLE 35 AUSTRALIA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 36 AUSTRALIA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 37 SOUTH KOREA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)

TABLE 38 SOUTH KOREA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 39 SOUTH KOREA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 40 REST OF ASIA-PACIFIC: PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)

TABLE 41 REST OF ASIA-PACIFIC: PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 42 REST OF ASIA-PACIFIC: PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 43 REST OF THE WORLD: PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)

TABLE 44 REST OF THE WORLD: PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 45 REST OF THE WORLD: PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 46 MIDDLE EAST: PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)

TABLE 47 MIDDLE EAST: PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 48 MIDDLE EAST: PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 49 AFRICA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)

TABLE 50 AFRICA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 51 AFRICA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

TABLE 52 LATIN AMERICA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)

TABLE 53 LATIN AMERICA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE, 2019-2032 (USD BILLION)

TABLE 54 LATIN AMERICA: PULMONARY ARTERIAL HYPERTENSION MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET

FIGURE 4 GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, SHARE (%), BY DRUG CLASS, 2023

FIGURE 5 GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, SHARE (%), BY TYPE, 2023

FIGURE 6 GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, SHARE (%), BY ROUTE OF ADMINISTRATION, 2023

FIGURE 7 GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, SHARE (%), BY REGION, 2023

FIGURE 8 NORTH AMERICA: PULMONARY ARTERIAL HYPERTENSION MARKET, SHARE (%), BY REGION, 2023

FIGURE 9 EUROPE: PULMONARY ARTERIAL HYPERTENSION MARKET, SHARE (%), BY REGION, 2023

FIGURE 10 ASIA-PACIFIC: PULMONARY ARTERIAL HYPERTENSION MARKET, SHARE (%), BY REGION, 2023

FIGURE 11 REST OF THE WORLD: PULMONARY ARTERIAL HYPERTENSION MARKET, SHARE (%), BY REGION, 2023

FIGURE 12 GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: COMPANY SHARE ANALYSIS, 2023 (%)

FIGURE 13 UNITED THERAPEUTICS CORPORATION: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 14 UNITED THERAPEUTICS CORPORATION: SWOT ANALYSIS

FIGURE 15 JOHNSON & JOHNSON: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 16 JOHNSON & JOHNSON: SWOT ANALYSIS

FIGURE 17 VIATRIS INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 18 VIATRIS INC.: SWOT ANALYSIS

FIGURE 19 BAYER: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 20 BAYER: SWOT ANALYSIS

FIGURE 21 SANDOZ INC..: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 22 SANDOZ INC..: SWOT ANALYSIS

FIGURE 23 GILEAD SCIENCES, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 24 GILEAD SCIENCES, INC.: SWOT ANALYSIS

FIGURE 25 LUPIN PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 26 LUPIN PHARMACEUTICALS, INC.: SWOT ANALYSIS

FIGURE 27 GLAXOSMITHKLINE: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 28 GLAXOSMITHKLINE: SWOT ANALYSIS

FIGURE 29 NOVARTIS INTERNATIONAL AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 30 NOVARTIS INTERNATIONAL AG: SWOT ANALYSIS

FIGURE 31 TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 32 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS

FIGURE 33 SUN PHARMACEUTICAL INDUSTRIES, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 34 SUN PHARMACEUTICAL INDUSTRIES, INC.: SWOT ANALYSIS

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

FEATURES	LICENCE TYPE
FEATURES	Single User	Multiuser Licence	Enterprise User
Price	$ 4,950	$ 5,950	$ 7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout The Organization.
Free Customization
Direct access to the Analyst
Deliverable Format
Deliverable Format
Platform Access
Discount on Your Next Purchase	10%	15%	10%
Printable Versions

Why Choose Market Research Future?

Leading companies partner with us for data-driven Insights